About Enochian Biopharma
Enochian developes an innovative proprietary technology in the field of HIV/AIDS.
9 articles with Enochian Biopharma
The company said that it values the FDA's feedback and is happy that the agency has accepted its request to provide insights on its Hepatitis B development program.
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
– Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced that the FDA has accepted a Pre-IND request for a potential cure of hepatitis B virus infection.
Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology
Enochian BioSciences, Inc. announced that the company has acquired an exclusive license for an innovative technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza.
Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, announced that the FDA has accepted a Pre-IND request for a potential functional cure or treatment of HIV.
The FDA accepted its pre-Investigational New Drug request for a cell therapy treatment that could be a key factor in controlling HIV.
• First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster Presentation - http://www.enochianbio.com/wp-content/uploads/2020/05/Final-Poster-SyngeneicMouse_431_ASGCT_Poster_Final-05112020-2.pdf Slide Presentation - http://www.enochianbio.com/wp-content/uploads/2020/05/Final-Presentation-SyngeneicMouse_431_ASGCT_Final-05112020.pdf - A second study provides
DanDrit Biotech USA, Inc. finalized its acquisition of Enochian Biopharma Inc. on February 16, 2018.
DanDrit Biotech USA, Inc. announced the completion of its previously reported acquisition of Enochian Biopharma Inc.
DanDrit plans to change its name to Enochian ImmunoScience and relocate to Los Angeles, California.